228 related articles for article (PubMed ID: 18975354)
61. How aggressive should initial therapy for rheumatoid arthritis be? The Finnish experience.
Kaarela K; Hakala M; Hannonen P; Kautiainen H; Korpela M; Leirisalo-Repo M; Luosujärvi R; Luukkainen R; Möttönen T; Puolakka K
Rheumatology (Oxford); 2005 Jan; 44(1):134-5; author reply 135-6. PubMed ID: 15611310
[No Abstract] [Full Text] [Related]
62. Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis.
Boers M
Ann Rheum Dis; 2009 Jan; 68(1):1-2. PubMed ID: 19088258
[No Abstract] [Full Text] [Related]
63. Recent advances in drug therapy for rheumatoid arthritis.
Malaviya AN; Kaushik P
J Assoc Physicians India; 1999 Sep; 47(9):912-7. PubMed ID: 10778664
[No Abstract] [Full Text] [Related]
64. Assessment and management of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
[TBL] [Abstract][Full Text] [Related]
65. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
Okada Y; Nawata M; Tanaka Y
Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
[TBL] [Abstract][Full Text] [Related]
66. [Analysis of the action of butyric acid that downregulates tumor necrosis factor alpha expression in rheumatoid synovial cells].
Fukae J
Hokkaido Igaku Zasshi; 2004 Jan; 79(1):27-39. PubMed ID: 14978972
[No Abstract] [Full Text] [Related]
67. Regulators of cytokine signalling in rheumatoid arthritis.
Rahman A
Rheumatology (Oxford); 2007 Dec; 46(12):1745-6. PubMed ID: 17986480
[No Abstract] [Full Text] [Related]
68. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
Haraoui B
J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
[No Abstract] [Full Text] [Related]
69. Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by Khanna et al.
Morgan SL; Baggott JE; Alarcón GS
Arthritis Rheum; 2006 May; 54(5):1708-9; author reply 1709-10. PubMed ID: 16646062
[No Abstract] [Full Text] [Related]
70. How antirheumatic drugs protect joints from damage in rheumatoid arthritis.
Schett G; Stach C; Zwerina J; Voll R; Manger B
Arthritis Rheum; 2008 Oct; 58(10):2936-48. PubMed ID: 18821703
[No Abstract] [Full Text] [Related]
71. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers.
Bresnihan B; Pontifex E; Thurlings RM; Vinkenoog M; El-Gabalawy H; Fearon U; Fitzgerald O; Gerlag DM; Rooney T; van de Sande MG; Veale D; Vos K; Tak PP
J Rheumatol; 2009 Aug; 36(8):1800-2. PubMed ID: 19671815
[TBL] [Abstract][Full Text] [Related]
72. Recent therapeutic advances in the treatment of rheumatoid arthritis.
Jonas BL
N C Med J; 2007; 68(6):425-6. PubMed ID: 18236860
[No Abstract] [Full Text] [Related]
73. [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
Kaliterna DM
Reumatizam; 2008; 55(2):60-1. PubMed ID: 19024277
[TBL] [Abstract][Full Text] [Related]
74. Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al.
Parker CT; Rennie T
Arthritis Rheum; 2004 Sep; 50(9):3051; author reply 3051-2. PubMed ID: 15457479
[No Abstract] [Full Text] [Related]
75. Cytokines in rheumatoid arthritis. Localization in arthritic joint tissue and regulation in vitro.
Deleuran BW
Scand J Rheumatol Suppl; 1996; 104():1-34. PubMed ID: 8668952
[No Abstract] [Full Text] [Related]
76. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.
Tanino M; Matoba R; Nakamura S; Kameda H; Amano K; Okayama T; Nagasawa H; Suzuki K; Matsubara K; Takeuchi T
Biochem Biophys Res Commun; 2009 Sep; 387(2):261-5. PubMed ID: 19577537
[TBL] [Abstract][Full Text] [Related]
77. [Effects of intermittent negative pressure on mRNA expression of osteoprotegerin and osteoprotegerin ligand in human BMSCs].
Yang Z; Zhang Y; Liu M; Guo X; Xu P
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Nov; 22(11):1354-7. PubMed ID: 19068606
[TBL] [Abstract][Full Text] [Related]
78. Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerization domain 2 in rheumatoid arthritis synovial fibroblasts.
Ospelt C; Brentano F; Jüngel A; Rengel Y; Kolling C; Michel BA; Gay RE; Gay S
Arthritis Rheum; 2009 Feb; 60(2):355-63. PubMed ID: 19180502
[TBL] [Abstract][Full Text] [Related]
79. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors.
Fili S; Karalaki M; Schaller B
Cancer Lett; 2009 Sep; 283(1):10-9. PubMed ID: 19201081
[TBL] [Abstract][Full Text] [Related]
80. Efficacy of combination therapy in rheumatoid arthritis: comment on the review by Smolen et al.
Möttönen T; Hannonen P; Leirisalo-Repo M; Korpela M; Hakala M; Kautiainen H;
Arthritis Rheum; 2006 Jun; 54(6):2032-4; author reply 2034-5. PubMed ID: 16732573
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
